Washington Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Washington Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,400	Closed	-$291K	–	108
2017 Q2	$291K	Hold	2,400	–	–	0.33%	84
2017 Q1	$271K	Hold	2,400	–	–	0.31%	90
2016 Q4	$261K	Hold	2,400	–	–	0.32%	87
2016 Q3	$395K	Hold	2,400	–	–	0.54%	73
2016 Q2	$342K	Buy	+2,400	New	+$350K	0.49%	79

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Washington Capital Management's ICPT Position: Q3 2017 in Review

Washington Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 2,400 shares — an estimated $291K sold.

Washington Capital Management first reported a position in ICPT in Q2 2016 and held it in 5 quarters. The position peaked at $395K in Q3 2016. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

Washington Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Washington Capital Management sold 2,400 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $291K.
Washington Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 5 quarters.
Washington Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $395K in Q3 2016.
155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Washington Capital Management's 13F filing for Q3 2017, filed 9 Nov 2017.